Aadi Bioscience DB:3350 Rapport sur les actions Finances de l'entreprise + 4 Analystes
Aadi Bioscience, Inc.
DB:3350 Rapport sur les actions
Capitalisation boursière : €48.7m
Ajouter à la liste de surveillance3350 Aperçu des actions Aadi Bioscience, Inc. est une société biopharmaceutique qui développe et commercialise des thérapies de précision pour les cancers génétiquement définis présentant des altérations dans les gènes de la voie mTOR.
Récompenses Analyse des risques Voir tous les contrôles de risques Aadi Bioscience, Inc. Concurrents Historique des prix et performances
Résumé des plus hauts, des changements et des baisses de prix pour Aadi Bioscience Historique des cours de bourse Prix actuel de l'action US$1.91 Plus haut sur 52 semaines US$4.82 Plus bas sur 52 semaines US$1.18 Bêta 0.37 1Variation sur 1 mois 7.91% Variation sur 3 mois 52.80% Variation sur 1 an -54.31% 3Variation sur 3 ans -90.73% Variation sur 5 ans n/a Évolution depuis l'introduction en bourse -90.87%
Nouvelles et mises à jour récentes
Aadi Bioscience, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 31 Aadi Bioscience, Inc. Approves Plan of Termination That Will Result in Workforce Reduction of 22 Employees, Representing Approximately 32% of the Workforce Aug 23
Aadi Bioscience Provides PRECISION1 Trial Updates Aug 21
Second quarter 2024 earnings released: US$0.54 loss per share (vs US$0.67 loss in 2Q 2023) Aug 08
Aadi Bioscience, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Aug 01
Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Small Cap Comp Value Index Jul 03 Voir plus de mises à jour
Aadi Bioscience, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 31 Aadi Bioscience, Inc. Approves Plan of Termination That Will Result in Workforce Reduction of 22 Employees, Representing Approximately 32% of the Workforce Aug 23
Aadi Bioscience Provides PRECISION1 Trial Updates Aug 21
Second quarter 2024 earnings released: US$0.54 loss per share (vs US$0.67 loss in 2Q 2023) Aug 08
Aadi Bioscience, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Aug 01
Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Small Cap Comp Value Index Jul 03
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting May 24
New minor risk - Profitability May 10
Forecast to breakeven in 2026 May 09
First quarter 2024 earnings released: US$0.68 loss per share (vs US$0.57 loss in 1Q 2023) May 08
Aadi Bioscience, Inc., Annual General Meeting, Jun 11, 2024 Apr 28
Full year 2023 earnings released: US$2.44 loss per share (vs US$2.69 loss in FY 2022) Mar 14
Aadi Bioscience, Inc. to Report Q4, 2023 Results on Mar 13, 2024 Mar 07 Aadi Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Feb 13
Aadi Bioscience, Inc. Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations Dec 15
Third quarter 2023 earnings released: US$0.60 loss per share (vs US$0.68 loss in 3Q 2022) Nov 10
New minor risk - Market cap size Oct 19
Aadi Bioscience, Inc. Announces Executive Changes Oct 05
Second quarter 2023 earnings released: US$0.67 loss per share (vs US$0.87 loss in 2Q 2022) Aug 10
Aadi Bioscience, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Aug 03
First quarter 2023 earnings released: US$0.57 loss per share (vs US$0.66 loss in 1Q 2022) May 10
High number of new directors Apr 20
High number of new directors Feb 16
High number of new directors Jan 25
Aadi Bioscience, Inc. Announces Management Changes Nov 29
High number of new directors Nov 21
Third quarter 2022 earnings released: US$0.68 loss per share (vs US$9.17 loss in 3Q 2021) Nov 10 Aadi Bioscience, Inc. Announces Executive Changes, Effective January 1, 2023
Aadi Bioscience, Inc. Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-Sirolimus at 34th EORTC-NCI-AACR Symposium Oct 13
Now 21% undervalued Oct 01
Second quarter 2022 earnings released: US$0.87 loss per share (vs US$0.22 loss in 2Q 2021) Aug 11
Aadi Bioscience, Inc. Reports Impairment of Intangible Asset for the Second Quarter Ended June 30, 2022 Aug 11
Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Microcap Value Index Jun 26
Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications Jun 02
Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications Jun 01
Aadi Bioscience, Inc. Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Present at 2022 ASCO Annual Meeting May 27
High number of new directors May 26
First quarter 2022 earnings released: US$0.66 loss per share (vs US$0.71 loss in 1Q 2021) May 13 Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders May 10
Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services May 05
High number of new directors Apr 29
Aadi Bioscience, Inc. Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes Apr 01
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 18
Less than half of directors are independent Mar 01
Aadi Bioscience, Inc. Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa Feb 24
Interim Chief Financial Officer Lance Thibault has left the company Dec 01
Aadi Bioscience, Inc. Announces FDA Approval of Its First Product Fyarro™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa) Nov 24
No independent directors Sep 01 Rendement pour les actionnaires 3350 DE Biotechs DE Marché 7D 8.5% -0.009% -1.2% 1Y -54.3% -17.6% 9.0%
Voir le rapport complet des actionnaires
Rendement vs Industrie: 3350 a sous-performé le secteur German Biotechs qui a rapporté -17.6 % au cours de l'année écoulée.
Rendement vs marché: 3350 a sous-performé le marché German qui a rapporté 9 % au cours de l'année écoulée.
Volatilité des prix Is 3350's price volatile compared to industry and market? 3350 volatility 3350 Average Weekly Movement 6.3% Biotechs Industry Average Movement 6.2% Market Average Movement 4.8% 10% most volatile stocks in DE Market 10.8% 10% least volatile stocks in DE Market 2.4%
Cours de l'action stable: 3350 n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.
Volatilité au fil du temps: La volatilité hebdomadaire de 3350 a diminué de 11% à 6% au cours de l'année écoulée.
À propos de l'entreprise Aadi Bioscience, Inc. est une société biopharmaceutique qui développe et commercialise des thérapies de précision pour les cancers génétiquement définis présentant des altérations dans les gènes de la voie mTOR. Son principal produit candidat est FYARRO, une forme de particules liées aux protéines de sirolimus pour suspension injectable destinée au traitement des patients adultes atteints d'un PECome malin avancé, non résécable ou métastatique. La société participe également à l'évaluation de FYARRO dans des cancers, notamment dans des indications ciblant des altérations génomiques spécifiques qui activent la voie mTOR.
Afficher plus Aadi Bioscience, Inc. Résumé des fondamentaux Comment les bénéfices et les revenus de Aadi Bioscience se comparent-ils à sa capitalisation boursière ? 3350 statistiques fondamentales Capitalisation boursière €48.75m Bénéfices(TTM) -€58.10m Recettes(TTM ) €23.61m
Bénéfices et recettes Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM) 3350 compte de résultat (TTM ) Recettes US$25.07m Coût des recettes US$52.61m Marge brute -US$27.54m Autres dépenses US$34.15m Les revenus -US$61.69m
Derniers bénéfices déclarés
Sep 30, 2024
Prochaine date de publication des résultats
s/o
Résultat par action (EPS) -2.50 Marge brute -109.86% Marge bénéficiaire nette -246.06% Ratio dettes/capitaux propres 0%
Quelles ont été les performances à long terme de 3350?
Voir les performances historiques et les comparaisons
Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}